Experience the 2020 Quality & Regulatory Global Summit On Demand

This virtual event featured more than 20 sessions over 4 days covering the highest priority issues facing today's senior quality, regulatory and IT professionals.

Access the complimentary on-demand sessions to learn from quality, regulatory, and product claims experts from the consumer goods, chemical and cosmetics industries about the strategies and tactics they’re using to transform vision into value.

 

    News, Awards & Press

    More than 200 Companies Select Veeva Regulatory Applications to Streamline Regulatory Operations

    Organizations are leveraging Veeva solutions to keep pace with changing regulations

    PLEASANTON, CA — February 6, 2020 — Veeva Systems (NYSE:VEEV) today announced an increasing number of life sciences companies are adopting applications in the Veeva Vault RIM Suite to streamline regulatory information management. More than 200 companies are now using Vault RIM applications to modernize their regulatory business operations for faster submission development and better visibility across processes for improved compliance.

    “It is critical to have the right processes and systems in place to leverage regulatory information freely across functions and borders,” said Regina Freunscht, vice president and global head of regulatory operations at Merck Healthcare KGaA, Darmstadt, Germany. “Veeva Vault RIM gives us a modern cloud application to streamline submissions and improve visibility into global regulatory processes.”

    Vault RIM brings together regulatory content and data to give life sciences companies of all sizes one authoritative source for product registration information, submission documents, published dossiers, and health authority interactions. Companies can automate workflows to get the right documents to the right people for approval, eliminating the need for multiple systems and manual tracking spreadsheets that slow execution and increase compliance risk.

    Veeva continues to deliver new innovations in Veeva Vault that improve how teams work together. Veeva Vault’s new collaborative authoring with Microsoft Office enables multiple users to simultaneously author and edit documents in Microsoft Office desktop applications directly from Veeva Vault. Now regulatory teams can seamlessly collaborate on submission documents for improved control and productivity.

    “Global markets and continuously evolving regulations such as IDMP increase complexity and introduce greater challenges for regulatory teams preparing and reviewing submissions,” said John Lawrie, vice president, Veeva Vault RIM. “Veeva is committed to delivering continued innovation that helps the industry streamline regulatory information management and adapt to new regulatory data standards so customers have more flexibility to keep pace with changing regulations.”

    The Veeva Vault RIM Suite includes Vault Registrations, Vault Submissions, Vault Submissions Publishing, and Vault Submissions Archive for fully integrated RIM capabilities on a single cloud platform. Vault RIM is part of Veeva Development Cloud, a unified suite of applications for clinical, regulatory, quality, and safety to help organizations drive end-to-end business processes across R&D and manufacturing.

    Join Veeva, Viela Bio, Radius Health, and Alexion Pharmaceuticals at DIA RSIDM Forum on Feb. 11, from 4:15 p.m. – 5:30 p.m., to learn more about how life sciences companies are streamlining regulatory processes and accelerating end-to-end submission development.

    Additional Information
    For more on Veeva Vault RIM Suite, visit: veeva.com/RIM
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
    Follow @veevasystems on Twitter: twitter.com/veevasystems
    Like Veeva on Facebook: facebook.com/veevasystems

    About Veeva Systems
    Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 800 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

    Forward-looking Statements
    This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

    ###

    Contact:
    Roger Villareal
    Veeva Systems
    925-264-8885
    roger.villareal@veeva.com

    Lisa Barbadora
    Veeva Systems
    610-420-3413
    pr@veeva.com

    Download PDF